InvestorsHub Logo
Followers 42
Posts 5751
Boards Moderated 0
Alias Born 04/12/2021

Re: None

Tuesday, 12/27/2022 8:59:21 PM

Tuesday, December 27, 2022 8:59:21 PM

Post# of 151
The latest filing showed strong revenues (page f-28) despite China’s economy being closed and disrupted etc in 2022, China has today announced it is reopening its economy. The acquisition of Zhongrun shares provides for 75% ownership of Zhongrun, a pharma company, and the OS is below 10 million which is about what their bottom line value is after expenses and liabilities, should grow revenues from here and maybe, hopefully, become a major company in China with one of those big SP numbers going forward, as they have in home medical service that with lockdowns being over should accelerate that portion of their business. The Chinese government should promote this company’s services.

https://www.otcmarkets.com/filing/html?id=16176697&guid=Lml-kazCb8puB3h#F20F2022_EHOMEHOUSE_HTM_a_028

“Zhongrun, which operates as a drug wholesaler and logistics distributor specializing in all kinds of traditional (patent) Chinese medicines, antibiotics, dietary supplements and medical devices.

Zhongrun has entered and will seek to expand partnership with hospitals, clinics and drug stores in China to grow sales and also supply key herb ingredients for the production of specialized Chinese medicines that are rooted in ancient knowledge and principles.

Some of the ingredients provided by Zhongrun have been used for thousands of years as key herbs in traditional Chinese medicine, which may have health effects, such as lowering blood pressure, alleviating cold and flu symptoms, reducing pain and enhancing immune system against contagious diseases.

Mr. Wenshan Xie, Chairman and CEO of E-Home, commented: “Chinese traditional medicine has a long history. With more Chinese people exploring new health trends, we believe traditional Chinese medicine products with health-preserving and healthcare effects have significant growing potential. The acquisition of Zhongrun gives E-Home opportunities to enter into the big health and Chinese medicinal products industry. We will leverage our advantages to provide our clients with effective and high-quality supply chain and healthcare services. Meanwhile the expanded sales of Chinese traditional medicine products will also help safeguard our Company’s business performance.”“

Having the ability to access medical products and distribute them effectively will be key as China’s borders are reopened, leading to major export opportunities to neighboring countries.

my posts are always theory and not financial advice

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EJH News